The estimated Net Worth of Ricardo Zayas is at least 688 千$ dollars as of 8 June 2010. Ricardo Zayas owns over 1,195 units of Catalent stock worth over 649,490$ and over the last 15 years Ricardo sold CTLT stock worth over 38,790$.
Ricardo has made over 1 trades of the Catalent stock since 2010, according to the Form 4 filled with the SEC. Most recently Ricardo sold 1,195 units of CTLT stock worth 38,790$ on 8 June 2010.
The largest trade Ricardo's ever made was selling 1,195 units of Catalent stock on 8 June 2010 worth over 38,790$. On average, Ricardo trades about 199 units every 0 days since 2009. As of 8 June 2010 Ricardo still owns at least 10,892 units of Catalent stock.
You can see the complete history of Ricardo Zayas stock trades at the bottom of the page.
Ricardo's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over 2,686,980,380$ worth of Catalent stock and bought 123,000 units worth 5,376,345$ . The most active insiders traders include Management Associates V L.L...、Peter Zippelius、Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of 22,866,018$. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth 39,429$.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: